Indivior is pioneering the development and discovery of treatment strategies for OUD, as well as exploring new therapies to potentially address the needs of people suffering from alcohol, stimulant and cannabis use disorders.
Indivior’s R&D has led to a range of daily and monthly treatment options for patients with moderate-to -severe opioid use disorder. We also developed a monthly treatment option for the treatment of schizophrenia in adult patients.
To learn more about our commercially launched products, please visit the products page.
Brand Name/Product Candidate
Preclinical
Phase 1
Phase 2
Phase 3
Regulatory Approval
Commercial Launch
-
Treatment of Cannabis Use Disorder
AEF0117* Cannabinoid-1 receptor synthetic signaling specific inhibitor
-
Treatment of Opioid Use Disorder
INDV-6001** is a sustained-release LAI prodrug of buprenorphine
-
Treatment for Opioid Use Disorder
INDV-2000 selective orexin-1 receptor antagonist
-
Treatment for Alcohol Use Disorder
INDV-1000*** Gamma-aminobutyric acid subtype B (GABAB) positive allosteric modulator (PAM)
-
Treatment for Acute Cannabinoid Overdose
INDV-5004@ cannabinoid-1 receptor antagonist
